Product Description
TRIA-662 (1-methylnicotinamide chloride, 1-MNA chloride) is a naturally occurring, major metabolite of nicotinic acid and a nicotinamide, two main forms of the B3vitamin. (Sourced from: http://cortria.com)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cortria
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hyperlipoproteinemias|Hyperlipidemia
Phase 2: Hyperlipidemia|Lipidoses|Hypertriglyceridemia|Hyperlipoproteinemias|Hyperlipoproteinemia Type V
Phase 1: Healthy Volunteers|Hypertension|Body Temperature Changes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01809301 |
BPSI-1479 | P1 |
Completed |
Healthy Volunteers |
2013-05-01 |
2019-03-19 |
Treatments |
|
NCT01930240 |
Cortria-002 | P1 |
Completed |
Hypertension|Body Temperature Changes |
2008-01-01 |
2019-03-19 |
Treatments |
|
NCT02008084 |
1-methylnicotinamide Chloride | P2 |
Completed |
Hyperlipoproteinemia Type V|Lipidoses|Hyperlipidemia|Hypertriglyceridemia|Hyperlipoproteinemias |
2015-10-01 |
2019-03-20 |
Treatments |
|
NCT00758303 |
Cortria-001 | P3 |
Completed |
Hyperlipidemia|Hyperlipoproteinemias |
2008-12-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|